Eptinezumab (Vyepti) (Eptinezumab-jjmr) for Personal Injury

Drug Class: CGRP Ligand Monoclonal Antibody — Preventive (Quarterly IV Infusion)

Common Uses

  • Preventive treatment of episodic migraine
  • Preventive treatment of chronic migraine
  • Post-traumatic migraine following car accidents, whiplash, or TBI
  • Patients requiring the highest-efficacy CGRP option administered by infusion

How It Helps in Personal Injury Cases

Eptinezumab (Vyepti) is the most clinically distinctive injectable CGRP antibody — it is the only one administered as an intravenous infusion rather than subcutaneous injection. Quarterly IV infusion in a clinical setting generates both pharmacy records (drug dispensed to infusion center) and infusion center medical records, creating the richest documentation profile of any CGRP drug. The 300mg dose is associated with the most robust efficacy in chronic migraine and represents the highest per-administration cost in the CGRP antibody class.

Eptinezumab neutralizes the CGRP ligand via IV administration over 30 minutes, achieving 100% bioavailability immediately (versus 50-70% for subcutaneous injections) and providing measurable pain freedom on day 1 of the first post-treatment migraine in approximately 26% of patients at 300mg — the fastest onset of any CGRP preventive. Quarterly administration maintains CGRP suppression for three months.

Eptinezumab (Vyepti) for Post-Traumatic Migraine Prevention

Eptinezumab, sold as Vyepti, is the only CGRP monoclonal antibody administered as an intravenous infusion rather than a subcutaneous injection. Quarterly IV infusion in a clinical setting makes it the most comprehensively documented CGRP preventive in personal injury cases.

The IV Difference

All other approved CGRP antibodies are self-administered subcutaneously. Vyepti is administered over 30 minutes in an infusion center or neurology office. This clinical administration:

  • Achieves 100% bioavailability (vs. ~50-70% for subcutaneous drugs)
  • Produces measurable preventive effect beginning day 1 after infusion
  • Generates infusion center records in addition to pharmacy records
  • Requires prescriber involvement at each administration — documented in medical records

Dosing

  • 100mg IV quarterly
  • 300mg IV quarterly (higher efficacy, particularly for chronic migraine)

The 300mg dose demonstrated pain freedom on day 1 of first post-treatment migraine in 26% of patients versus 15% for placebo — the fastest-acting preventive in the CGRP class.

Clinical Evidence

The PROMISE-1 trial (episodic migraine) and PROMISE-2 trial (chronic migraine) demonstrated statistically significant reductions in monthly migraine days for both dose levels.

Documentation Profile in PI Cases

Vyepti generates the richest documentation of any CGRP drug:

  • Infusion center records documenting each quarterly infusion appointment
  • Pharmacy records for drug dispensed to the infusion center
  • Prescriber order records for each infusion

Four infusions per year = four complete clinical documentation events, each with multiple record types.

Accessing Eptinezumab Through LienScripts

Eptinezumab (Vyepti) is brand-name only. LienScripts provides pharmacy lien coverage at $0 upfront cost for qualified personal injury patients.

Dosage Forms

  • IV infusion 100mg over 30 minutes (quarterly)
  • IV infusion 300mg over 30 minutes (quarterly — higher efficacy dose)
  • Administered at infusion center or neurology office

Common Side Effects

  • Nasopharyngitis (stuffy/runny nose) — most common
  • Hypersensitivity/allergic reactions during infusion (rare but reason for in-office administration)
  • Fatigue
  • Urinary tract infection (uncommon)

Frequently Asked Questions

Why is Vyepti given as an IV infusion rather than an injection?

Eptinezumab was developed as an IV formulation to achieve 100% bioavailability — meaning the entire dose reaches the bloodstream immediately rather than being absorbed slowly from subcutaneous tissue. This produces measurable preventive benefit as early as the first day after infusion, faster than subcutaneous options.

Does IV infusion create more medical records than an injection?

Yes. Vyepti infusions generate infusion center records in addition to pharmacy records — creating two separate documented events per treatment. The infusion requires a clinical setting, patient monitoring, and a prescriber order that are all separately recorded.

How often are Vyepti infusions given?

Vyepti is infused every three months (quarterly). Each infusion takes approximately 30 minutes to administer.

Is there a generic or biosimilar for Vyepti?

No. Eptinezumab is available only as Vyepti with no biosimilar alternatives currently approved in the United States.